A phase 2, randomised, double-blind, placebo-controlled, dose-ranging study evaluating retatrutide was published in the New England Journal of Medicine (NEJM) in June 2023 (Jastreboff et al
The organisms need fuel to multiply and compete effectively against less desirable species
Results: Evidence indicates local estrogen dominance with progesterone resistance, pervasive immune dysregulation, and oxidative stress with iron-driven ferroptosis that particularly injures granulosa cells, alongside disease-relevant genetic/epigenetic regulators and reproductive-tract/gut microbiome dysbiosis
HCV promotes chronic infections by attacking liver cells, causing hepatic damage, and evading innate and adaptive immunity
Dizziness during semaglutide treatment may signal a blood pressure drop or other issue requiring dose adjustment or medical investigation